Search

Your search keyword '"Lutzky, Jose"' showing total 350 results
Start Over Author "Lutzky, Jose"
350 results on '"Lutzky, Jose"'

2. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

Author

In, Gino K, Ribeiro, Jennifer R, Yin, Jun, Xiu, Joanne, Bustos, Matias A, Ito, Fumito, Chow, Frances, Zada, Gabriel, Hwang, Lindsay, Salama, April KS, Park, Soo J, Moser, Justin C, Darabi, Sourat, Domingo-Musibay, Evidio, Ascierto, Maria L, Margolin, Kim, Lutzky, Jose, Gibney, Geoffrey T, Atkins, Michael B, Izar, Benjamin, Hoon, Dave SB, and VanderWalde, Ari M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Brain Disorders, Cancer, Inflammatory and immune system, Oncology and carcinogenesis
Abstract

Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are enriched in oxidative phosphorylation. Here, we report results from a multi-omic analysis of a large, real-world melanoma cohort. MBM exhibited lower interferon-gamma (IFNγ) scores and T cell-inflamed scores compared to primary cutaneous melanoma (PCM) or extracranial metastases (ECM), which was independent of tumor mutational burden. Among MBM, there were fewer computationally inferred immune cell infiltrates, which correlated with lower TNF and IL12B mRNA levels. Ingenuity pathway analysis (IPA) revealed suppression of inflammatory responses and dendritic cell maturation pathways. MBM also demonstrated a higher frequency of pathogenic PTEN mutations and angiogenic signaling. Oxidative phosphorylation (OXPHOS) was enriched in MBM and negatively correlated with NK cell and B cell-associated transcriptomic signatures. Modulating metabolic or angiogenic pathways in MBM may improve responses to immunotherapy in this difficult-to-treat patient subset.

Published
2023

3. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D’Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Brain Disorders, Brain Cancer, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Humans, Glioblastoma, Temozolomide, Prospective Studies, Brain Neoplasms, Recurrence, Dendritic Cells, Vaccination, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P

Published
2023

7. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.

Author

Ribas, Antoni, Algazi, Alain, Ascierto, Paolo A, Butler, Marcus O, Chandra, Sunandana, Gordon, Michael, Hernandez-Aya, Leonel, Lawrence, Donald, Lutzky, Jose, Miller, Wilson H, Campbell, Katie M, Delafont, Bruno, Marshall, Shannon, Mueller, Nancy, and Robert, Caroline

Subjects
Humans, Melanoma, Skin Neoplasms, Exanthema, Diarrhea, Oximes, Imidazoles, Pyridones, Pyrimidinones, Proto-Oncogene Proteins B-raf, Mitogen-Activated Protein Kinases, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Cohort Studies, Mutation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Young Adult, B7-H1 Antigen, Progression-Free Survival
Abstract

Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma. This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n = 26), or durvalumab and trametinib given concomitantly (cohort B, n = 20) or sequentially (cohort C, n = 22) for patients with BRAF-wild type melanoma. Adverse events and treatment discontinuation rates were more common than previously reported for these agents given as monotherapy. Objective responses were observed in 69.2% (cohort A), 20.0% (cohort B) and 31.8% (cohort C) of patients, with evidence of improved tumor immune infiltration and durable responses in a subset of patients with available biopsy samples. In conclusion, combined MAPK inhibition and anti-PD-L1 therapy may provide treatment options for patients with advanced melanoma.

Published
2020

9. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Brain Cancer, Neurosciences, Immunization, Clinical Research, Cancer, Brain Disorders, Rare Diseases, Patient Safety, Prevention, Vaccine Related, Orphan Drug, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Brain Neoplasms, Cancer Vaccines, Dendritic Cells, Endpoint Determination, Female, Glioblastoma, Humans, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Young Adult, Immunotherapy, Dendritic cell, Vaccine, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundStandard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma.MethodsAfter surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS).ResultsFor the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone.ConclusionsAddition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival. Trial registration Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&rank=1 ; initially registered 19 September 2002.

Published
2018

10. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Neurosciences, Brain Disorders, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

Published
2018

14. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Author

Carvajal, Richard D, Lawrence, Donald P, Weber, Jeffrey S, Gajewski, Thomas F, Gonzalez, Rene, Lutzky, Jose, O'Day, Steven J, Hamid, Omid, Wolchok, Jedd D, Chapman, Paul B, Sullivan, Ryan J, Teitcher, Jerrold B, Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R, Heinrich, Michael C, Bastian, Boris C, Corless, Christopher L, Fletcher, Jonathan A, and Hodi, F Stephen

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Brain Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Female, Humans, Male, Melanoma, Middle Aged, Proto-Oncogene Proteins c-kit, Pyrimidines, Skin Neoplasms, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAlthough durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown.Experimental designWe conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases. The primary endpoint was 4-month disease control rate. Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS). A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, respectively.ResultsTwenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B). Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint. Two partial responses were observed in cohort A (18.2%; 90% CI, 3%-47%); none were observed in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 months) and 9.1 months (90% CI, 4.3-14.2 months), respectively, in all treated patients.ConclusionsNilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy. The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited.

Published
2015

15. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Author

Antonia, Scott J., Balmanoukian, Ani, Brahmer, Julie, Ou, Sai-Hong I., Hellmann, Matthew D., Kim, Sang-We, Ahn, Myung-Ju, Kim, Dong-Wan, Gutierrez, Martin, Liu, Stephen V., Schöffski, Patrick, Jäger, Dirk, Jamal, Rahima, Jerusalem, Guy, Lutzky, Jose, Nemunaitis, John, Calabrò, Luana, Weiss, Jared, Gadgeel, Shirish, Bhosle, Jaishree, Ascierto, Paolo A., Rebelatto, Marlon C., Narwal, Rajesh, Liang, Meina, Xiao, Feng, Antal, Joyce, Abdullah, Shaad, Angra, Natasha, Gupta, Ashok K., Khleif, Samir N., and Segal, Neil H.

Published
2019
Full Text
View/download PDF

16. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

17. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

18. 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial

Author

Patel, Sapna P, primary, Carvajal, Richard, additional, Montazeri, Kamaneh, additional, Reddy, Sunil, additional, Lutzky, Jose, additional, Khan, Shaheer A, additional, Chmielowski, Bartosz, additional, Bhatia, Shailender, additional, Medina, Theresa, additional, Haymaker, Cara, additional, Sheth, Rahul, additional, Kuban, Joshua D, additional, Thornton, Lindsay, additional, Wehrenberg-Klee, Eric, additional, Novelli, Paula, additional, Lucci, Anthony, additional, Sarli, Vanessa, additional, Meas, Salyna, additional, Cox, Bryan, additional, LaPorte, Jason, additional, Guha, Prajna, additional, Ghosh, Chandra C, additional, Hulstine, Ann-Marie, additional, Knight, Robert, additional, Moody, Ashley, additional, Geller, David, additional, Katz, Steven, additional, Orloff, Marlana, additional, and Davar, Diwakar, additional

Published
2023
Full Text
View/download PDF

19. Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Author

Larkin, James, primary, Del Vecchio, Michele, primary, Mandalá, Mario, primary, Gogas, Helen, primary, Arance Fernandez, Ana M., primary, Dalle, Stéphane, primary, Cowey, Charles Lance, primary, Schenker, Michael, primary, Grob, Jean-Jacques, primary, Chiarion-Sileni, Vanna, primary, Marquez-Rodas, Ivan, primary, Butler, Marcus O., primary, Di Giacomo, Anna Maria, primary, Middleton, Mark R., primary, Lutzky, Jose, primary, de la Cruz-Merino, Luis, primary, Arenberger, Petr, primary, Atkinson, Victoria, primary, Hill, Andrew G., primary, Fecher, Leslie A., primary, Millward, Michael, primary, Nathan, Paul D., primary, Khushalani, Nikhil I., primary, Queirolo, Paola, primary, Ritchings, Corey, primary, Lobo, Maurice, primary, Askelson, Margarita, primary, Tang, Hao, primary, Dolfi, Sonia, primary, Ascierto, Paolo A., primary, and Weber, Jeffrey, primary

Published
2023
Full Text
View/download PDF

20. Data from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Author

Larkin, James, primary, Del Vecchio, Michele, primary, Mandalá, Mario, primary, Gogas, Helen, primary, Arance Fernandez, Ana M., primary, Dalle, Stéphane, primary, Cowey, Charles Lance, primary, Schenker, Michael, primary, Grob, Jean-Jacques, primary, Chiarion-Sileni, Vanna, primary, Marquez-Rodas, Ivan, primary, Butler, Marcus O., primary, Di Giacomo, Anna Maria, primary, Middleton, Mark R., primary, Lutzky, Jose, primary, de la Cruz-Merino, Luis, primary, Arenberger, Petr, primary, Atkinson, Victoria, primary, Hill, Andrew G., primary, Fecher, Leslie A., primary, Millward, Michael, primary, Nathan, Paul D., primary, Khushalani, Nikhil I., primary, Queirolo, Paola, primary, Ritchings, Corey, primary, Lobo, Maurice, primary, Askelson, Margarita, primary, Tang, Hao, primary, Dolfi, Sonia, primary, Ascierto, Paolo A., primary, and Weber, Jeffrey, primary

Published
2023
Full Text
View/download PDF

21. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Author

Clark, Joseph I., Wong, Michael K.K., Kaufman, Howard L., Daniels, Gregory A., Morse, Michael A., McDermott, David F., Agarwala, Sanjiv S., Lewis, Lionel D., Stewart, John H., Vaishampayan, Ulka, Curti, Brendan, Gonzalez, René, Lutzky, Jose, Rudraptna, Venkatesh, Cranmer, Lee D., Jeter, Joanne M., Hauke, Ralph J., Miletello, Gerald, Milhem, Mohammed M., Amin, Asim, Richart, John M., Fishman, Mayer, Hallmeyer, Sigrun, Patel, Sapna P., Van Veldhuizen, Peter, Agarwal, Neeraj, Taback, Bret, Treisman, Jonathan S., Ernstoff, Marc S., Perritt, Jessica C., Hua, Hong, Rao, Tharak B., Dutcher, Janice P., and Aung, Sandra

Published
2017
Full Text
View/download PDF

22. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Author

Larkin, James, primary, Del Vecchio, Michele, additional, Mandalá, Mario, additional, Gogas, Helen, additional, Arance Fernandez, Ana M., additional, Dalle, Stéphane, additional, Cowey, Charles Lance, additional, Schenker, Michael, additional, Grob, Jean-Jacques, additional, Chiarion-Sileni, Vanna, additional, Marquez-Rodas, Ivan, additional, Butler, Marcus O., additional, Di Giacomo, Anna Maria, additional, Middleton, Mark R., additional, Lutzky, Jose, additional, de la Cruz-Merino, Luis, additional, Arenberger, Petr, additional, Atkinson, Victoria, additional, Hill, Andrew G., additional, Fecher, Leslie A., additional, Millward, Michael, additional, Nathan, Paul D., additional, Khushalani, Nikhil I., additional, Queirolo, Paola, additional, Ritchings, Corey, additional, Lobo, Maurice, additional, Askelson, Margarita, additional, Tang, Hao, additional, Dolfi, Sonia, additional, Ascierto, Paolo A., additional, and Weber, Jeffrey, additional

Published
2023
Full Text
View/download PDF

23. Abstract 4114: Can exosomal cargoes predict checkpoint inhibitor response in melanoma, and can we overcome drug resistance

Author

Puente, Pablo Eduardo, primary, Nguyen, Dan, additional, Savaraj, Niramol, additional, Wu, Chunjing, additional, Wangpaichitr, Medhi, additional, Roche, Stephane, additional, Zhao, Guangkuan, additional, Richaud, Alexis, additional, Lutzky, Jose, additional, Aya, Leonel Hernandez, additional, Moller, Mecker, additional, Crystal, Jessica, additional, Goel, Neha, additional, and Feun, Lynn, additional

Published
2023
Full Text
View/download PDF

24. Supplemental Table 1 from Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Author

Carvajal, Richard D., primary, Lawrence, Donald P., primary, Weber, Jeffrey S., primary, Gajewski, Thomas F., primary, Gonzalez, Rene, primary, Lutzky, Jose, primary, O'Day, Steven J., primary, Hamid, Omid, primary, Wolchok, Jedd D., primary, Chapman, Paul B., primary, Sullivan, Ryan J., primary, Teitcher, Jerrold B., primary, Ramaiya, Nikhil, primary, Giobbie-Hurder, Anita, primary, Antonescu, Cristina R., primary, Heinrich, Michael C., primary, Bastian, Boris C., primary, Corless, Christopher L., primary, Fletcher, Jonathan A., primary, and Hodi, F. Stephen, primary

Published
2023
Full Text
View/download PDF

25. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Author

Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, Bosch, Marnix L, Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after rec

Published
2023

27. 787 DELTA-1: a global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

Author

Gastman, Brian, primary, Sarnaik, Amod, additional, Lawrence, Donald, additional, Olszanski, Anthony, additional, Chmielowski, Bartosz, additional, Lutzky, Jose, additional, Butler, Marcus, additional, Hamid, Omid, additional, Corrie, Pippa, additional, Domingo-Musibay, Evidio, additional, Thomas, Sajeve, additional, Thistlethwaite, Fiona, additional, Daniels, Gregory, additional, Evans, Thomas, additional, Furness, Andrew, additional, Gibney, Geoffrey, additional, Harries, Mark, additional, Medina, Theresa, additional, Olson, Daniel, additional, Pallan, Lalit, additional, Whitman, Eric, additional, Wilson, Melissa, additional, Aycock, Jeff, additional, Hawkins, Robert, additional, Jiang, Yizhou, additional, Kennedy, Audrey, additional, Robbins, Paul, additional, Roberts, Zachary, additional, and Gall, John Le, additional

Published
2022
Full Text
View/download PDF

28. CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

Author

Liau, Linda M, primary, Ashkan, Keyoumars, additional, Brem, Steven, additional, Campian, Jian, additional, Trusheim, John, additional, Iwamoto, Fabio, additional, Tran, David, additional, Anstass, George, additional, Cobbs, Charles, additional, Heth, Jason, additional, Salacz, Michael, additional, D'Andre, Stacy, additional, Aiken, Robert, additional, Moshel, Yaron, additional, Nam, JooYeon, additional, Pillainayagam, Clement, additional, Wagner, Stephanie, additional, Walter, Kevin, additional, Chaudary, Rekha, additional, Goldlust, Samuel, additional, Lee, Ian, additional, Bota, Daniela, additional, Elinzano, Heinrich, additional, Grewal, Jai, additional, Lillehei, Kevin, additional, Mikkelsen, Tom, additional, Walbert, Tobias, additional, Abram, Steve, additional, Brenner, Andrew, additional, Ewend, Matthew, additional, Khagi, Simon, additional, Lovick, Darren, additional, Portnow, Jana, additional, Kim, Lyndon, additional, Loudon, William, additional, Martinez, Nina, additional, Thompson, Reid, additional, Avigan, David, additional, Fink, Karen, additional, Geoffroy, Francois, additional, Giglio, Pierre, additional, Gligich, Oleg, additional, Krex, Dietmar, additional, Lindhorst, Scott M, additional, Lutzky, Jose, additional, Meisel, Hans-Joerg, additional, Nadji-Ohl, Minou, additional, Sanchin, Lhagva, additional, Sloan, Andrew, additional, and Bosch, Marnix, additional

Published
2022
Full Text
View/download PDF

30. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

Author

Atkinson, Thomas M., Hay, Jennifer L., Shoushtari, Alexander, Li, Yuelin, Paucar, Daniel J., Smith, Sloane C., Kudchadkar, Ragini R., Doyle, Austin, Sosman, Jeffrey A., Quevedo, Jorge Fernando, Milhem, Mohammed M., Joshua, Anthony M., Linette, Gerald P., Gajewski, Thomas F., Lutzky, Jose, Lawson, David H., Lao, Christopher D., Flynn, Patrick J., Albertini, Mark R., Sato, Takami, Lewis, Karl, Marr, Brian, Abramson, David H., Dickson, Mark Andrew, Schwartz, Gary K., and Carvajal, Richard D.

Published
2017
Full Text
View/download PDF

32. Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Author

Khan, Shaheer, primary, Lutzky, Jose, additional, Shoushtari, Alexander N., additional, Jeter, Joanne, additional, Marr, Brian, additional, Olencki, Thomas E., additional, Cebulla, Colleen M., additional, Abdel-Rahman, Mohamed, additional, Harbour, J. William, additional, Sender, Naomi, additional, Nesson, Alexandra, additional, Singh-Kandah, Shahnaz, additional, Hernandez, Susana, additional, King, Jeanelle, additional, Katari, Manpreet S., additional, Dimapanat, Lyssa, additional, Izard, Stephanie, additional, Ambrosini, Grazia, additional, Surriga, Oliver, additional, Rai, Alex J., additional, Chiuzan, Codruta, additional, Schwartz, Gary K., additional, and Carvajal, Richard D., additional

Published
2022
Full Text
View/download PDF

33. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Author

Sanborn, Rachel E, primary, Pishvaian, Michael J, additional, Callahan, Margaret K, additional, Weise, Amy, additional, Sikic, Branimir I, additional, Rahma, Osama, additional, Cho, Daniel C, additional, Rizvi, Naiyer A, additional, Sznol, Mario, additional, Lutzky, Jose, additional, Bauman, Julie E, additional, Bitting, Rhonda L, additional, Starodub, Alexander, additional, Jimeno, Antonio, additional, Reardon, David A, additional, Kaley, Thomas, additional, Iwamoto, Fabio, additional, Baehring, Joachim M, additional, Subramaniam, Deepa S, additional, Aragon-Ching, Jeanny B, additional, Hawthorne, Thomas R, additional, Rawls, Tracey, additional, Yellin, Michael, additional, and Keler, Tibor, additional

Published
2022
Full Text
View/download PDF

36. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Author

Sullivan, Ryan J., Atkins, Michael B., Kirkwood, John M., Agarwala, Sanjiv S., Clark, Joseph I., Ernstoff, Marc S., Fecher, Leslie, Gajewski, Thomas F., Gastman, Brian, Lawson, David H., Lutzky, Jose, McDermott, David F., Margolin, Kim A., Mehnert, Janice M., Pavlick, Anna C., Richards, Jon M., Rubin, Krista M., Sharfman, William, Silverstein, Steven, Slingluff, Jr, Craig L., Sondak, Vernon K., Tarhini, Ahmad A., Thompson, John A., Urba, Walter J., White, Richard L., Whitman, Eric D., Hodi, F. Stephen, and Kaufman, Howard L.

Published
2018
Full Text
View/download PDF

38. Abstract 5625: Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma

Author

Hernandez-Aya, Leonel F., primary, Rodriguez, Estelamari, additional, Nallagangula, Aparna, additional, Yin, Jun, additional, Walker, Phillip, additional, Xiu, Joanne, additional, Moser, Justin, additional, In, Gino K., additional, Spetzler, David, additional, Gibney, Geoffery T., additional, Oberley, Matthew, additional, Phung, Thuy, additional, Atkins, Michael, additional, Hoon, Dave S., additional, Korn, Wolfgang Michael, additional, Lutzky, Jose, additional, and Lopes, Gilberto, additional

Published
2022
Full Text
View/download PDF

39. Abstract 6130: Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma

Author

In, Gino K., primary, Yin, Jun, additional, Walker, Phillip, additional, Moser, Justin, additional, Xiu, Joanne, additional, Poorman, Kelsey, additional, Gibney, Geoffery T., additional, Oberley, Matthew, additional, Phung, Thuy, additional, Hernandez-Aya, Leonel F., additional, Lutzky, Jose, additional, Korn, Wolfgang Michael, additional, and Atkins, Michael B., additional

Published
2022
Full Text
View/download PDF

40. Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).

Author

Lutzky, Jose, primary, Marron, Thomas Urban, additional, Powell, Steven Francis, additional, Johnson, Daniel H., additional, Patel, Manish, additional, El-Khoueiry, Anthony B., additional, Sarantopoulos, John, additional, Dadi-Mehmetaj, Saida, additional, Russell, Luke, additional, Russell, Stephen J., additional, Peng, Kah Whye, additional, Kaesshaefer, Stephen, additional, Gullo, Giuseppe, additional, Bexon, Alice Susannah, additional, and Sznol, Mario, additional

Published
2022
Full Text
View/download PDF

41. A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).

Author

Haydon, Andrew Mark, primary, Khushalani, Nikhil I., additional, Robert, Caroline, additional, Brungs, Daniel, additional, Collichio, Frances A., additional, Colevas, A. Dimitrios, additional, Lim, Annette May Ling, additional, Kudchadkar, Ragini Reiney, additional, Chai-Ho, Wanxing, additional, Daniels, Gregory A., additional, Lutzky, Jose, additional, Lee, Jenny HJ, additional, Silk, Ann W., additional, Lebbe, Celeste, additional, Grob, Jean-Jacques, additional, Smith, Margaret, additional, Fury, Matthew G., additional, Alamgeer, Muhammad, additional, Hill, Andrew Graham, additional, and Migden, Michael Robert, additional

Published
2022
Full Text
View/download PDF

42. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma

Author

In, Gino Kim, primary, Nallagangula, Aparna, additional, Choi, Jacob Seung, additional, Tachiki, Lisa, additional, Blackburn, Matthew J, additional, Capone, Stephen, additional, Bollin, Kathryn B, additional, Reuben, Daniel Y., additional, Shirai, Keisuke, additional, Zhang-Nunes, Sandy, additional, Ragab, Omar, additional, Terando, Alicia, additional, Hu, Jenny C., additional, Lee, Han, additional, Bhatia, Shailender, additional, Chandra, Sunandana, additional, Lutzky, Jose, additional, and Gibney, Geoffrey Thomas, additional

Published
2022
Full Text
View/download PDF

43. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

Author

Andtbacka, Robert H. I., primary, Curti, Brendan, additional, Daniels, Gregory A., additional, Hallmeyer, Sigrun, additional, Whitman, Eric D., additional, Lutzky, Jose, additional, Spitler, Lynn E., additional, Zhou, Karl, additional, Bommareddy, Praveen K., additional, Grose, Mark, additional, Wang, Meihua, additional, Wu, Cai, additional, and Kaufman, Howard L., additional

Published
2021
Full Text
View/download PDF

44. 547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma

Author

Haydon, Andrew, primary, Alamgeer, Muhammad, additional, Brungs, Daniel, additional, Collichio, Frances, additional, Khushalani, Nikhil, additional, Colevas, Dimitrios, additional, Rischin, Danny, additional, Kudchadkar, Ragini, additional, Chai-Ho, Wanxing, additional, Daniels, Gregory, additional, Lutzky, Jose, additional, Lee, Jenny, additional, Bowyer, Samantha, additional, Migden, Michael, additional, Silk, Ann, additional, Lebbe, Celeste, additional, Grob, Jean-jaques, additional, Melero, Ignacio, additional, Sheladia, Piyush, additional, Bommareddy, Praveen, additional, He, Shui, additional, Andreu-Vieyra, Claudia, additional, Fury, Matthew, additional, and Hill, Andrew, additional

Published
2021
Full Text
View/download PDF

45. 550 ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies

Author

Luke, Jason, primary, Migden, Michael, additional, Chai-Ho, Wanxing, additional, Bolotin, Diana, additional, Wise-Draper, Trisha, additional, Poklepovic, Andrew, additional, Laux, Douglas, additional, Kheterpal, Meenal, additional, Verschraegen, Claire, additional, Collichio, Frances, additional, Lutzky, Jose, additional, Daniels, Gregory, additional, Tsai, Katy, additional, Navia, Susan, additional, Castro, Henry, additional, Bommareddy, Praveen, additional, Pirzkall, Andrea, additional, and Coffin, Robert, additional

Published
2021
Full Text
View/download PDF

49. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Author

Slingluff, Craig L, primary, Lewis, Karl D, additional, Andtbacka, Robert, additional, Hyngstrom, John, additional, Milhem, Mohammed, additional, Markovic, Svetomir N, additional, Bowles, Tawnya, additional, Hamid, Omid, additional, Hernandez-Aya, Leonel, additional, Claveau, Joel, additional, Jang, Sekwon, additional, Philips, Prejesh, additional, Holtan, Shernan G, additional, Shaheen, Montaser F, additional, Curti, Brendan, additional, Schmidt, William, additional, Butler, Marcus O, additional, Paramo, Juan, additional, Lutzky, Jose, additional, Padmanabhan, Arvinda, additional, Thomas, Sajeve, additional, Milton, Daniel, additional, Pecora, Andrew, additional, Sato, Takami, additional, Hsueh, Eddy, additional, Badarinath, Suprith, additional, Keech, John, additional, Kalmadi, Sujith, additional, Kumar, Pallavi, additional, Weber, Robert, additional, Levine, Edward, additional, Berger, Adam, additional, Bar, Anna, additional, Beck, J Thaddeus, additional, Travers, Jeffrey B, additional, Mihalcioiu, Catalin, additional, Gastman, Brian, additional, Beitsch, Peter, additional, Rapisuwon, Suthee, additional, Glaspy, John, additional, McCarron, Edward C, additional, Gupta, Vinay, additional, Behl, Deepti, additional, Blumenstein, Brent, additional, and Peterkin, Joanna J, additional

Published
2021
Full Text
View/download PDF

50. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Author

Olson, Daniel J., primary, Eroglu, Zeynep, additional, Brockstein, Bruce, additional, Poklepovic, Andrew S., additional, Bajaj, Madhuri, additional, Babu, Sunil, additional, Hallmeyer, Sigrun, additional, Velasco, Mario, additional, Lutzky, Jose, additional, Higgs, Emily, additional, Bao, Riyue, additional, Carll, Timothy C., additional, Labadie, Brian, additional, Krausz, Thomas, additional, Zha, Yuanyuan, additional, Karrison, Theodore, additional, Sondak, Vernon K., additional, Gajewski, Thomas F., additional, Khushalani, Nikhil I., additional, and Luke, Jason J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results